Investors & Media

Whats new.

Press releases

Press releases.

Immutep Announces Expansion of TACTI-002 Collaboration Trial

November 19th 2020
press releases

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

November 19th 2020
press releases

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

November 10th 2020
press releases

Investor updates

Investor updates.

Investor Update - August 2020

August 17th 2020
investor updates

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates

Analyst reports

Analyst reports.

Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete

November 19th 2020
analyst reports

Maxim - The Data for Efti in Lung and H&N Continues to Build – Raising PT to $4, from $2

November 11th 2020
analyst reports

goetzpartners securities - Striking support for efti - checkpoint inhibitor combos

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

November 11th 2020
analyst reports